Charging cancer drugmaker Roche over pricing could backfire
09 February 2022 - 17:42
UPDATED 09 February 2022 - 23:58
The Competition Commission has charged multinational drug company Roche over alleged excessive pricing of its patented breast cancer drug Herceptin in a move that could deter companies from bringing high-cost and novel medicines to SA.
The commission says tens of thousands of women are being denied life-saving treatment because of the drug’s price tag. The commission wants the Competition Tribunal, which acts like a court, to fine Roche 10% of its annual turnover from 2011 to 2019...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.